Pliant Therapeutics Stock Today
| PLRX Stock | USD 12.85 0.12 0.94% |
Performance0 of 100
| Odds Of DistressLess than 21
|
Pliant Therapeutics is trading at 12.85 as of the 22nd of November 2024; that is 0.94 percent increase since the beginning of the trading day. The stock's open price was 12.73. Pliant Therapeutics has about a 21 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for Pliant Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 3rd of December 2022 and ending today, the 22nd of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 3rd of June 2020 | Category Healthcare | Classification Health Care |
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California. The company has 60.85 M outstanding shares of which 7.22 M shares are at this time shorted by private and institutional investors with about 17.04 trading days to cover. More on Pliant Therapeutics
Moving against Pliant Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Pliant Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsPliant Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Pliant Therapeutics' financial leverage. It provides some insight into what part of Pliant Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pliant Therapeutics (PLRX) is traded on NASDAQ Exchange in USA. It is located in 260 Littlefield Avenue, South San Francisco, CA, United States, 94080 and employs 166 people. Pliant Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 774.67 M. Pliant Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 60.85 M outstanding shares of which 7.22 M shares are at this time shorted by private and institutional investors with about 17.04 trading days to cover.
Pliant Therapeutics currently holds about 163.6 M in cash with (116.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.36.
Check Pliant Therapeutics Probability Of Bankruptcy
Ownership AllocationThe majority of Pliant Therapeutics outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Pliant Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Pliant Therapeutics. Please pay attention to any change in the institutional holdings of Pliant Therapeutics as this could imply that something significant has changed or is about to change at the company.
Check Pliant Ownership Details
Pliant Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Trv Gp Iv, Llc | 2024-09-30 | 2.1 M | |
| Polar Capital Holdings Plc | 2024-06-30 | 2 M | |
| Deutsche Bank Ag | 2024-06-30 | 1.5 M | |
| State Street Corp | 2024-06-30 | 1.4 M | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.3 M | |
| Geode Capital Management, Llc | 2024-06-30 | 1.3 M | |
| Ra Capital Management, Llc | 2024-06-30 | 1.3 M | |
| Pictet Asset Manangement Sa | 2024-06-30 | 1.2 M | |
| Franklin Resources Inc | 2024-06-30 | 1 M | |
| Deep Track Capital, Lp | 2024-09-30 | 6 M | |
| Blackrock Inc | 2024-06-30 | 5 M |
Pliant Therapeutics Historical Income Statement
Pliant Stock Against Markets
Pliant Therapeutics Corporate Management
| Hal MD | Scientific Board | Profile | |
| Mike Ouimette | Gen Sec | Profile | |
| Rik Derynck | Scientific Board | Profile | |
| Dean MD | Scientific Board | Profile | |
| Johannes Hull | Chief Officer | Profile | |
| MBA MD | CEO Pres | Profile | |
| Christopher Keenan | Vice Communications | Profile |
Additional Tools for Pliant Stock Analysis
When running Pliant Therapeutics' price analysis, check to measure Pliant Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pliant Therapeutics is operating at the current time. Most of Pliant Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pliant Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pliant Therapeutics' price. Additionally, you may evaluate how the addition of Pliant Therapeutics to your portfolios can decrease your overall portfolio volatility.